Waldenström macroglobulinemia is a rare and indolent B-cell lymphoma characterized by the accumulation of malignant lymphoplasmacytic cells in the bone marrow and, crucially, by the overproduction of monoclonal immunoglobulin M, an antibody protein that thickens the blood and can cause hyperviscosity, neuropathy, and organ damage. Because the disease is uncommon, most treatment evidence comes from small trials and single-arm studies, leaving clinicians with genuine uncertainty when patients relapse after frontline therapy. This rarity is precisely why the French group’s multicenter approach matters: by pooling patients from 17 centers, the investigators assembled one of the larger cohorts ever reported for this specific treatment strategy.

The drug at the center of the study, venetoclax, belongs to a class of agents known as BH3 mimetics. These small molecules bind to BCL-2, an anti-apoptotic protein that many B-cell cancers exploit to evade programmed cell death. By occupying the BCL-2 binding groove, venetoclax releases the cellular brakes on apoptosis, allowing malignant lymphocytes to self-destruct. The drug has already transformed the treatment landscape for chronic lymphocytic leukemia, and earlier monotherapy studies suggested promising activity in relapsed or refractory Waldenström macroglobulinemia, a population with significant unmet medical need. What remained unclear was whether venetoclax should be given alone or in combination with other agents in this disease.

The WAVE investigators turned to real-world clinical practice to answer that question. The 46 patients included in the analysis had received a median of three prior lines of treatment before starting venetoclax, and 89 percent had already been exposed to a Bruton tyrosine kinase inhibitor, the class of drugs that has become a cornerstone of Waldenström macroglobulinemia therapy. This detail is important: these were heavily pretreated patients whose disease had already evaded the most effective modern targeted therapies, meaning that any meaningful response signal carries real clinical weight. Among the cohort, 25 patients, or 54 percent, received venetoclax combined with an anti-CD20 antibody, typically rituximab or a related monoclonal antibody that targets the CD20 surface protein found on B cells and recruits the immune system to destroy antibody-coated tumor cells.

The headline finding concerns response depth. At the time of best response, patients treated with the combination achieved a deep response rate, defined as very good partial response plus uncertain complete response, of 56 percent, compared with just 24 percent among those treated with venetoclax monotherapy, a difference that reached statistical significance with a p value of 0.03. In lymphoma care, depth of response is not an academic nicety. Deeper remissions, particularly those in which the monoclonal IgM protein falls to very low or undetectable levels, are consistently associated with longer periods of disease control before relapse. For a disease in which the abnormal protein itself drives many of the symptoms, pushing IgM down as far as possible translates directly into clinical benefit.

Perhaps more striking was the result of the multivariate analysis. When the investigators adjusted for other clinical variables, anti-CD20 combination therapy emerged as the only factor independently associated with achieving a deep response, with a hazard ratio of 4.07 and a p value of 0.03. In other words, the antibody combination quadrupled the odds of a deep remission regardless of other patient characteristics. This kind of signal, emerging from a retrospective dataset where treatment assignment was not randomized, cannot prove causation on its own, but it provides a strong rationale for the prospective trials that the authors say are needed to confirm the strategy.

The progression-free survival data reinforced the same direction of benefit, though with more statistical uncertainty. At two years, 78 percent of patients treated with venetoclax plus anti-CD20 had not experienced disease progression or death, compared with 54 percent of those on monotherapy. The confidence intervals were wide, spanning 54 to 90 percent for the combination arm and 27 to 74 percent for monotherapy, and the difference did not reach statistical significance with a p value of 0.25. That lack of formal significance is unsurprising given the modest sample size, but the magnitude of the gap, nearly 25 percentage points at two years, is the kind of signal that clinicians and trial designers take seriously.

Safety, as always in combination therapy, is the counterweight to efficacy, and here the picture was more nuanced. Grade 3 or higher adverse events occurred in 17 patients, or 68 percent, of those receiving the combination, versus 7 patients, or 33 percent, of those on venetoclax alone, a difference that was statistically significant with a p value of 0.02. Three cases of febrile aplasia, episodes of fever accompanied by severe suppression of blood cell production, were reported, though these did not differ significantly between the two groups. The increased toxicity of the combination is consistent with what is known about adding antibody therapy to targeted agents: the pairing amplifies immune-mediated tumor killing but also increases the burden on the bone marrow and the immune system. For a largely elderly patient population, this trade-off between deeper remissions and higher rates of serious side effects will need careful weighing in future prospective studies.

The WAVE study also illustrates a broader shift in how rare-cancer evidence is generated. Randomized trials in diseases with incidence rates as low as Waldenström macroglobulinemia’s can take years to accrue even modest numbers of patients, and many relapsed patients cannot wait. Retrospective multicenter cohorts like this one, harmonized across 17 institutions and analyzed with multivariate statistics, offer a pragmatic middle path: they capture the messy reality of clinical practice, including heterogeneous prior treatments and variable dosing schedules, and they generate hypothesis-driving signals that can justify the prospective studies that ultimately change guidelines. The French FILO network has been particularly productive in this regard, leveraging the centralized structure of French hematology care to assemble cohorts that individual centers never could.

For patients and their physicians, the practical message is cautiously encouraging. Venetoclax, with or without an anti-CD20 antibody, is an oral, targeted, chemotherapy-free approach for a disease that has historically been treated with rituximab-based chemoimmunotherapy, proteasome inhibitors, or BTK inhibitors. The WAVE data suggest that in the relapsed or refractory setting, particularly after BTK inhibitor exposure, the combination strategy offers the best chance of a deep and durable response, at the cost of more frequent severe side effects. The authors themselves frame the findings as warranting further evaluation in prospective studies, and that is the appropriate note of restraint. Until randomized data arrive, the study gives hematologists a real-world benchmark and gives patients with few remaining options a reason for measured optimism that the next generation of trials will refine exactly who benefits most from this two-pronged attack on their cancer.

Subject of Research: Venetoclax with or without anti-CD20 antibody therapy for relapsed or refractory Waldenström macroglobulinemia

Article Title: Relapsed/refractory WAldenström macroglobulinemia patients treated by VEnetoclax with or without anti-CD20 antibody: WAVE a retrospective study of the French CLL/WM group (FILO)

Article References: Vonfeld, M., Systchenko, T., Debureaux, P.-E., Dupuis, J., Roos-Weil, D., Ysebaert, L., Dilhuydy, M.-S., Malphettes, M., Croizier, C., Aurran, T., Inchiappa, L., Willems, L., Hivert, B., Lévy, V., Bussot, L., Bouclet, F., Laribi, K., Clavert, A., Durand, A., & Tomowiak, C. (2026). Relapsed/refractory WAldenström macroglobulinemia patients treated by VEnetoclax with or without anti-CD20 antibody: WAVE a retrospective study of the French CLL/WM group (FILO). Annals of Hematology. https://doi.org/10.1007/s00277-026-07293-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07293-6

Keywords: Waldenström macroglobulinemia, venetoclax, anti-CD20 antibody, BTK inhibitor, relapsed refractory lymphoma, BCL-2, targeted therapy, retrospective study, hematology, monoclonal antibody, progression-free survival, FILO

CAR T cell therapy represents a paradigm shift in oncology, harnessing genetically engineered autologous T cells designed to recognize and eradicate malignant B cells via the CD19 antigen. While remarkable in its efficacy for many patients with relapsed or refractory LBCL, the therapy’s success rate plateaus with fewer than half achieving long-lasting remission. This variability has propelled an urgent need to unravel how the tumor microenvironment influences CAR T cell activity and persistence. The MD Anderson study, encompassing single-cell analyses of over 1.8 million cells derived from 232 patient biopsy samples, provides the most expansive cellular landscape to date, enabling an unprecedented resolution of the non-malignant cellular milieu.

Central to the investigation was the development of “LymphoMAPs,” detailed cellular and molecular maps of the lymphoma microenvironment annotated with clinical outcomes. These maps revealed three primary microenvironmental categories, each associated with differential benefit from CD19 CAR T cell therapy. The first subgroup, described as the fibroblast/macrophage-dominant milieu, is characterized by a scarcity of T cells and an overrepresentation of cancer-associated fibroblasts. Patients with tumors of this nature exhibited mixed but overall positive responses to CAR T cell therapy, indicating partial yet significant clinical benefit when compared to chemotherapy alone.

The second and most responsive group, labeled as the lymph node-like microenvironment, displayed abundant infiltrating T cells supplemented by non-hematopoietic stromal cells reminiscent of normal lymph node architecture. This supportive niche appears to foster CAR T cell expansion, persistence, and cytotoxic activity, correlating strongly with superior patient outcomes. The intimate interaction between T cells and stromal components underscores a cooperative ecosystem that potentiates immunotherapeutic efficacy, illustrating the importance of preserving or mimicking such microenvironmental conditions in therapeutic design.

Conversely, the third group, defined by an exhausted T cell phenotype, is marked by a predominance of CD8+ T cells exhibiting functional exhaustion alongside activated macrophages. This immunologically suppressive environment confers resistance to CAR T cell therapy, with patients showing negligible benefit compared to standard treatment modalities. These findings illuminate critical therapeutic challenges, emphasizing the need for alternative or adjunct targeted interventions capable of reversing T cell exhaustion or modulating macrophage activation to restore effective antitumor immunity.

This stratification of LBCL patients based on microenvironmental profiling marks a pivotal stride toward precision medicine, enabling clinicians to tailor therapeutic regimens not only to tumor-intrinsic factors but also to the surrounding cellular context. Moreover, the integration of these results with data from the ZUMA-7 Phase III clinical trial, which compared axicabtagene ciloleucel (axi-cel) — a CAR T cell product — against standard chemotherapy, lends robust validation and clinical relevance to the classification system.

The implications of this research reverberate widely across the immuno-oncology landscape. By delineating the microenvironmental determinants of CAR T cell responsiveness, the study identifies actionable targets and biological pathways that may be exploited to overcome resistance mechanisms. For instance, the exhaustion group could benefit from checkpoint inhibitors or agents that reprogram macrophage phenotype, potentially synergizing with CAR T cells to unlock therapeutic efficacy in refractory cases.

Further, the characterization of the fibroblast/macrophage niche invites exploration into how cancer-associated fibroblasts modulate immune infiltration and function, presenting avenues for interventions aiming to remodel the tumor stroma. Similarly, replicating aspects of the lymph node microenvironment ex vivo or in treatment protocols might enhance CAR T cell fitness and antitumor activity.

The research team at MD Anderson underscores the necessity for collaborative clinical trials integrating targeted therapies informed by these microenvironmental insights. Such trials are poised to refine patient selection, optimize combinatorial regimens, and ultimately improve survival outcomes across the heterogeneous landscape of LBCL. The philanthropic support of donors Beatriz and Ed Schweitzer and institutional funding from the MD Anderson Lymphoid Malignancies Program facilitated this landmark study, reflecting the critical impact of sustained investment in translational cancer research.

As the oncology community seeks to unravel the complexities of lymphoma and immunotherapy resistance, this comprehensive cellular atlas forged through advanced single-cell technologies offers a beacon toward more nuanced, effective, and individualized treatments. By confronting the intricate interplay between malignant B cells and their non-malignant neighbors, researchers are charting a path from descriptive biology to actionable clinical innovation, mirroring the broader shift in cancer care toward precision and personalization.

This ambitious mapping of lymphoma’s microenvironment not only elevates the scientific understanding of tumor-immune dynamics but also empowers clinicians with predictive tools to navigate the evolving therapeutic landscape. As trials expand and novel agents emerge, the integration of microenvironmental profiling into routine diagnostic workflows could become standard practice, heralding a new era of biomarker-driven CAR T cell therapy selection and combination strategies. Ultimately, these advances promise to extend the life-changing potential of immunotherapy to a broader cohort of patients battling large B-cell lymphoma.

Subject of Research: Large B-cell lymphoma tumor microenvironment profiling and immunotherapy response

Article Title: Researchers Identify Distinct Microenvironmental Subgroups in Large B-Cell Lymphoma Associated with CD19 CAR T Cell Therapy Outcomes

News Publication Date: June 18, 2025

Web References:
https://www.mdanderson.org/
https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00228-4

References:
Green, M. et al. (2025). Detailed profiling of lymphoma microenvironments reveals differential outcomes to CD19 CAR T cell therapy in large B-cell lymphoma. Cancer Cell.

Image Credits: Not provided

Keywords: Large B-cell lymphoma, CD19 CAR T cell therapy, tumor microenvironment, single-cell profiling, immunotherapy resistance, lymph node microenvironment, T cell exhaustion, cancer-associated fibroblasts, macrophages, precision medicine